Fig. 5
HCQ administration did not alter immune cell numbers in the spleen or blood. a The gating strategy of immune cells, including macrophages (CD11b+CD45hiLy6G−), neutrophils (CD11b+CD45hiLy6G+), B cells (CD45hiCD3−CD19+), and T cells (CD45hiCD3+CD19−), in the spleen and blood. b, c Representative images of the spleen and spleen indices of vehicle- and HCQ-treated TBI mice. n = 4 per group. The data are presented as the mean ± SD. *p < 0.05 vs. TBI + Vehicle group. d Representative FACS plots showing macrophages, neutrophils, T cells, and B cells in the spleen. e–h Quantification of the percentage of macrophages, neutrophils, T cells, and B cells in the spleen. n = 4 per group. The data are presented as the mean ± SD. ns: no significant difference. i Representative FACS panels of immune cells macrophage, neutrophils, T cells, and B cells in blood. j–m Quantification of the percentage of immune cells macrophage, neutrophils, T cells, and B cells in blood. n = 4 per group. The data are presented as the mean ± SD. *p < 0.05 vs. TBI + Vehicle group, ns: no significant difference